Secondary outcome measures (mean (SD)) before and after 4 weeks treatment with BFPE or placebo
| BFPE | Placebo | ||||
|---|---|---|---|---|---|
| Variable | Baseline (n=28) | 4 weeks (n=28) | Baseline (n=26) | Post 4 weeks (n=25) | Difference, BFPE minus placebo* (95% CI), p Value |
| FEV1 (L) | 3.61 (1.06) | 3.54 (0.98) | 3.56 (1.00) | 3.53 (1.06) | −0.07 (−0.20 to 0.06), p=0.26 |
| MMEF25–75 (L/min) | 160.5 (63.0) | 152.8 (60.6) | 155.5 (60.1) | 159.4 (67.3) | −11.8 (−22.6 to −1.0), p=0.034* |
| sRaw (kPa/s) | 1.12 (0.41) | 1.22 (0.38) | 1.21 (0.40) | 1.18 (0.44) | 0.09 (−0.06 to 0.24), p=0.22 |
| sGaw (kPa/s) | 0.99 (0.30) | 0.90 (0.25) | 0.91 (0.27) | 0.94 (0.28) | −0.07 (−0.18 to 0.03), p=0.17 |
| ACQ-5 | 0.74 (0.61) | 0.77 (0.61) | 0.62 (0.57) | 0.70 (0.76) | −0.06 (−0.37 to 0.25), p=0.72 |
| Eosinophils (×10^9 L) | 0.31 (0.14) | 0.32 (0.18)† | 0.33 (0.21) | 0.30 (0.16) | 0.01 (−0.05 to 0.08), p=0.69 |
†N=27 as no blood sample was available.
*Mixed linear model with baseline covariate.
ACQ-5, asthma control questionnaire; BFPE, berryfruit polyphenolic extract; FEV1, forced expiratory volume in 1 s; MMEF25–75, maximal mid expiratory flow; sGAW, specific airway conductance; sRAW, specific airway resistance.